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ABSTRACT 
West Nile Virus (WNV) and Japanese Encephalitis Virus (JEV) are positive sense, single-
stranded RNA viruses belonging to the family Flaviviridae, where the primary mode of 
transmission occurs through arthropod vectors such as mosquitos. WNV and JEV are the leading 
etiological agents for arboviral encephalitis in humans, and sporadic outbreaks continue to occur 
over time resulting in symptomatic infections that account for thousands of deaths each year. 
Although a number of vaccines have been developed to prevent JEV infections in highly 
endemic regions, issues with efficacy exist and the vaccine often fails to protect at risk 
populations from the development of encephalitis, which can be fatal. For both WNV and JEV, 
no clinically approved therapies currently exist for treatment of the central nervous system 
(CNS) involvement, which can lead to encephalitis, the most severe, and highly fatal form of the 
disease. Alpha-macroglobulins, which are physiological proteinase inhibitors have been shown 
to bind to viral proteins and enhance viral infections in vitro. Moreover, in humans alpha-
macroglobulins such as pregnancy zone protein (PZP) and alpha-2-macroglobulin (A2M) also 
serve as immune-modulatory proteins where their normal functions within the body include 
binding and shuttling of protease inhibitors, growth factors, cytokines, hormones, disease factors, 
and various small molecule nucleophilic ligands. Previous reports from our laboratory have 
shown the up-regulation of alpha-macroglobulins in wild type (WT) mice after a lethal 
subcutaneous WNV infection. Therefore, to define the role of a-macroglobulins during 
flavivirus infection in vivo, we investigated the susceptibility of mice deficient in a-
macroglobulins (PZP and MUG-1 double knockout; DKO) against lethal subcutaneous infection 
with either WNV or JEV. Results of our study show that DKO mice are completely resilient to 
lethal flaviviral infections of WNV and JEV. Likewise, DKO mice had a significantly milder 
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clinical disease through the course of the study, and this outcome can be coupled with the finding 
of significantly reduced viral burden in the blood, peripheral organs (kidney and spleen), and 
brains of the DKO mice when compared to WT mice. The DKO mice had a significantly reduced 
inflammatory response which was characterized by lower concentrations of pro-inflammatory 
cytokines and chemokines in the blood, spleen, and brain of DKO mice when compared to WT. 
Consistent with the multiplex immunoassay data, DKO mice also displayed a significantly 
decreased level of mRNA corresponding to immune genes in response to WNV infection when 
compared to WT. Overall, the data from this study demonstrates the significant impact that 
alpha-macroglobulins have in the pathogenesis of flavivirus-associated encephalitis in mice.  
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1.1 West Nile Virus:  
 
1.1.1 History 
 
West Nile Virus (WNV) is a neurotropic flavivirus that has spread across the globe and as a 
result has now become endemic to many regions of the world; however, the virus was originally 
isolated from a febrile 37-year-old woman participating in a malaria survey study in the West 
Nile district of Uganda in 1937.1 Following the original isolation and identification of the virus, 
various outbreaks have occurred in humans infrequently, with some of the most notable 
outbreaks occurring in Israel (1951 – 1954 and 1957), as well as in South Africa (1974). More 
recently, other sporadic outbreaks have also occurred in Romania and Morocco (1996), Tunisia 
(1997), Italy (1998), Russia, Israel, and the United States (1999), and Israel, France, and the 
United States (2000).2  
 
1.1.2 Epidemiology  
Prior to the introduction of WNV in the United States (US), epidemic arbovirus outbreaks were 
relatively scarce with the exception of sporadic outbreaks of another closely related flavivirus, 
St. Louis encephalitis virus (SLEV), causing outbreaks in the mid to late 1970’s. However, 
during 1999 in New York a cluster of human encephalitis cases occurred that was consistent with 
arboviral etiology, and the causative agent was later discovered to be WNV.3 Only three years 
after its initial introduction to the east coast of the United States, WNV had spread throughout 
the majority of the contiguous US and even into the neighboring countries of Canada and 
Mexico.4 Although symptomatic cases of WNV infection are not common in Central and South 
America, WNV has been detected during field surveillance efforts of vector specimens, which 
highlights the risk for a potential outbreak in human populations living in these regions as well. 
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To further highlight the spread of WNV, since its initial discovery in 1937 the virus has spread to 
the majority of the globe and is considered the most important causative agent for viral 
encephalitis worldwide.4 Figure 1 shows the global distribution of WNV by country, with the 
countries in red having human cases or human seropositivity, while the countries in blue show 
nonhuman or mosquito cases and seropositivity only. Countries in gray have no reported data, 
and the black lines represent the distribution of the mosquito vector (excluding the regions 
marked by dashed lines) and the circled numbers correspond to the number of lineages  of WNV 
reported in that area.4 
 
Figure 1: Global Distribution of WNV by Country4 
 
1.1.3 Virology  
WNV belongs to the genus Flavivirus which is within the family Flaviviridae. It has been 
classified as an arbovirus, meaning transmission occurs through arthropods, and in this case the 
female Culex mosquito is the culprit. WNV is an enveloped positive-sense single stranded RNA 
virus with a genome that is 11,029 nucleotides in length which code for ten viral proteins. Out of 
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the ten viral proteins three are considered structural proteins which have been termed the capsid 
(C), membrane (prM/M), and envelope (E); while the other seven proteins encoded by the WNV 
genome are considered nonstructural (NS) proteins and are numbered NS1, NS2A, NS2B, NS3, 
NS4A, NS4B, and NS5.5 Figure 2 shows a schematic diagram of the WNV genome, where one 
open reading frame is present and a distinction between structural and non-structural proteins is 
made on the figure. The resultant ten proteins are produced by proteolytic processing of the 
single polyprotein, and this is done so by the viral serine protease, or NS2B-NS3, as well as other 
host cellular proteases.5 
 
Figure 2: WNV Genome5 
 
To further demonstrate the organization of the WNV virion and genome, a schematic diagram of 
the WNV virion is shown in Figure 3. The center of the particle contains the RNA genome 
(green) which is then directly surrounded by the capsid protein (blue), followed by the 
membrane (yellow), and finally the outer coating of the virus particle which is made up of the 
pre-membrane/membrane (prM/M) protein (gray) as well as the envelope protein dimers (red).4  
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Figure 3: WNV Virion4 
 
1.1.4 Lifecycle and Replication 
The initial step in the lifecycle and replication of WNV is for the virus to bind to host cell 
receptors, which have yet to be fully elucidated, but this binding allows for the virus to enter host 
cells to hijack host cell machinery in order to replicate itself.5 The viral replication cycle is 
shown in Figure 4 where steps A through I correspond to important events that take place within 
the lifecycle of the virus upon infection of host cells. Upon entry into the cell via host cell 
receptor mediated endocytosis, the viral membrane goes through a low-pH fusion with the 
endosomal vesicle membrane which allows for the release of the viral genome into the cytoplasm 
of the cell, as shown in step A.5 The viral genome is then translated into a single polyprotein 
(shown in B) as previously mentioned, which is subsequently cleaved by the serine protease 
NS2B-NS3 as well as other host cellular proteases leaving the ten mature viral proteins, shown in 
C.5 A key step in the replication of WNV involves the RNA-dependent RNA polymerase 
(RdRp), NS5, as well as other proteins. In this step the enzyme RdRP as well as the other 
proteins copy complementary negative sense strands of RNA (shown in D) to be used 
subsequently as templates to synthesize new viral genetic materials (as shown in E and F). Virion 
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assembly occurs in the host rough endoplasmic reticulum (ER) membranes (as shown in G), then 
E and prM proteins on the surface of the virions are altered prior to the budding and release of 
the mature WNV particles (shown in H and I).5  
 
Figure 4: WNV Replication Cycle5 
 
1.1.5 WNV Clinical Disease  
Since its initial introduction to New York in 1999, there have been many cases of WNV 
infection in the United States resulting in consistent proportions of mortality in patients who 
develop West Nile Virus Neuroinvasive Disease (WNVND), ranging anywhere from 6% to 16%, 
or 2 to 276 total deaths annually, shown in Table 1.6 Although WNVND overall is considered 
rare and occurs in approximately 1% of total WNV infected people, neurological complications 
can have long lasting clinical implications and can potentially be fatal. High risk groups for 
development of WNVND after infection with WNV include the elderly, immunocompromised, 
and child populations, which is shown in Figure 5.7 Approximately 80% of total infections are 
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asymptomatic, meaning that the majority of individuals who become infected will likely be 
unaware; however, in the other 20% of infections symptomatic cases of WNV infection occur 
and the individual will experience a flu-like illness and show symptoms of  malaise, eye pain, 
headache, myalgia, gastro-intestinal discomfort and rash.8 In rare cases, approximately 1%, 
WNVND will develop and the individual may develop encephalitis, meningitis, or acute flaccid 
paralysis (AFP), and long-term neurological sequelae are common in more than 50% of these 
cases.8  
 
Table 1: CDC reported WNV disease cases and deaths6 
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Figure 5: CDC WNVND incidence6 
 
1.1.6 Therapeutics and Vaccines  
Unfortunately, to this date no clinically approved vaccines or treatment options for WNV disease 
are currently available for human use. There are, however, a number of ongoing clinical trials 
that are attempting to utilize treatment options such as interferon-alpha, corticosteroids, and 
WNV-specific immunoglobulin. Due to the fact that these clinical studies are ongoing, the 
overall efficacy of these treatment approaches has yet to be determined.9 Ribavirin, which is a 
clinically approved drug used to treat other viral infections such as Respiratory Syncytial Virus 
(RSV) and Hepatitis C virus, was administered to patients with WNV disease during an outbreak 
in Israel in 2000, but unfortunately these treated patients did not show any improvement 
compared to untreated controls.9 On the other hand, a vaccine approved for use in equine has 
been developed. Horses show a similar WNV disease process as that of humans in the sense that 
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severe neurological disease occurs in horses, which can ultimately lead to death or euthanasia.10 
Many vaccine platforms have been attempted for use in horses, however very limited data is 
available on the efficacy of these vaccines used in horses. Vaccine platforms such as inactivated 
whole virus vaccines, recombinant subunit vaccines, live attenuated or pseudo-infectious virion 
vaccines, live chimeric/recombinant virion vaccines, and DNA-vectored vaccines are currently 
being developed and tested in animals.11 Conversely, a vaccination approach for the prevention 
of WNV disease may not be the most ideal solution to the problem given the previous clinical 
data showing that the majority of the population remains asymptomatic after infection (~80%) 
and the majority of symptomatic infections result in a mild-febrile illness without CNS 
involvement.11 Due to these factors, a therapeutic treatment option that addresses the most severe 
forms of WNV disease rather than prophylactic vaccination seems to be the most logical 
approach in hopes of preventing mortality and long lasting neurological complications due to 
WNV infections. 
 
1.2 Japanese Encephalitis Virus: 
1.2.1 History 
Similar to WNV, Japanese Encephalitis virus (JEV) is a neurotropic flavivirus that is the leading 
cause of viral encephalitis in Asia.12 Japanese encephalitis (JE) outbreaks have been noted to 
occur as early as the 1800’s in Japan, but the first confirmed JEV case was reported in Japan in 
1924.12 Other sporadic cases have also been confirmed in Korea (1933), China (1940), the 
Philippines (1950), India (1955), and a number of other Asian countries thereafter. Over the past 
few decades the incidence of JE has increased in countries such as Bangladesh, Cambodia, India, 
Indonesia, and Pakistan.12 Currently, JEV affects approximately 25 Asian countries and 
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approximately 60% of the global population are at risk for infection with JEV. Another public 
health consideration for JEV is the absence of protective immunity for travelers who vacation to 
endemic regions where JEV transmission is ongoing through the mosquito vector.12  
 
1.2.2 Epidemiology 
Although JEV transmission and infection has been historically confined to its endemic regions in 
Asia, in the late 1990’s JEV emerged in the Torres Strait Islands where subsequent spread to the 
Cape York Peninsula occurred. This event alerted public health officials to the potential risk of a 
serious health threat to the population of Australia, and demonstrated a possible spread of the 
virus throughout the world.12 Figure 6 shows the geographic distribution of the four members of 
the JE serological group, and from the data it is clear that these viruses have the potential to 
spread globally through arthropod vectors and zoonotic reservoirs such as birds.12 In the early 
1970’s more than 100,000 cases of JE were reported each year with the vast majority of cases 
occurring in China.13 However more recently due to vaccination efforts, increased urbanization, 
changes in agricultural practices, and mosquito control the annual reported cases of JE has 
declined significantly, but around 30,000 cases are reported each year. Although these numbers 
may not be entirely accurate due to poor diagnostic and surveillance capabilities in those 
countries where JEV infections are common.13 JE can also be characterized as primarily a 
childhood disease because the vast majority of infections occur in children 15 years of age or 
less.13  
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Figure 6: Geographic distribution of four members of the JE serological group12 
 
1.2.3 Virology 
JEV is a member of the genus flavivirus and belongs to the family flaviviridae where it is 
considered the prototype virus of the JE serological group which includes the previously 
discussed viruses such WNV and SLEV, among others. Similar to WNV, JEV is a positive-sense 
single-stranded RNA virus where its 11 kilo-base genome encodes for a total of ten viral proteins 
where three are considered structural proteins (capsid, pre-membrane/membrane, and envelope), 
and the remaining seven are considered non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, 
NS4B, and NS5). For the case of JEV, an initial single polyprotein is translated and subsequently 
cleaved into the ten viral proteins which is a similar process to that of WNV.12 Figure 7 
represents a schematic diagram of the JEV genome and consequent gene expression.  
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Figure 7: JEV genome structure and gene expression12 
 
1.2.4 Lifecycle and Replication  
The lifecycle and replication of JEV is first initiated by the binding or attachment of an 
infectious virus particle to host cell receptors located on the plasma membrane. After the initial 
binding, the virus is internalized via receptor mediated endocytosis. Due to a low pH within the 
host cell endosome, conformational changes occur in the viral E glycoprotein which then triggers 
the fusion of the viral membrane to the host endosome membrane. As a result of this binding the 
virus particle uncoats and the genetic material of the virus, or the viral RNA, is released into the 
cytoplasm of the host cell. Due to the fact that JEV is a positive-sense single-stranded RNA 
virus, the viral RNA is then directly translated through utilization of host cell rough ER, which 
results in the formation of the single polyprotein as previously described. This polyprotein is 
then processed into the ten mature viral proteins which allow for subsequent viral genomic RNA 
replication within the host cell, while virus particle assembly also occurs inside the virus-
induced, ER-derived vesicles. Prior to budding, immature virion particles form a budding 
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complex where newly synthesized genomic RNA and C proteins associate in the lumen of the 
host ER. In the lumen of the host ER these immature virion particles then acquire the prM and E 
proteins on their membranes. The virions are still not yet considered mature and are transported 
to the host Golgi apparatus through the secretory pathway. Cleavage of the prM to M initiates the 
maturation of virus particles in the trans-Golgi network and the viral particles are then ready for 
budding, or release from the host cell. This process is achieved through exocytosis of the virus 
which results in progeny virus being released from the cell into the extracellular environment. 
Figure 8 illustrates the replication and lifecycle of JEV as previously described.12  
 
Figure 8: JEV replication cycle12 
 
1.2.5 JEV Clinical Disease 
With the majority of JEV infections being asymptomatic, an estimated <1% of people infected 
with the virus develop a clinical disease.13 JEV has been characterized to show an incubation 
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period ranging anywhere from 5 to 15 days, meaning that clinical signs and symptoms of illness 
due to JEV infection will not be present until 5 to 15 days after the initial infection has occurred. 
JEV disease can show a wide array of clinical signs and symptoms through the course of disease, 
usually beginning with an acute fever, headache, and vomiting which can then progress to more 
severe symptoms that are more suggestive of CNS involvement; for example, mental status 
change, focal neurological deficits, generalized weakness, and movement disorders.13 Among 
children infected with JEV seizures are common, however the classical description of JE 
includes a parkinsonian syndrome with mask-like facies, tremor, cogwheel rigidity, and 
choreoathetoid movements.13 Another clinical feature includes acute flaccid paralysis resembling 
poliomyelitis, and the most common complications associated with poor outcome and death due 
to JEV infection include status epilepticus, brain hypoxia, increased intracranial pressure, 
brainstem herniation, and aspiration pneumonia.13 Convulsions and abnormal behavior are 
common in children, whereas febrile illness and meningitis occur frequently in adults.12 JE has a 
case fatality ratio estimated to be between 20% - 30% and although some motor deficits and 
movement disorders improve after the acute illness, approximately 30% to 50% of JE survivors 
have neurologic or psychiatric sequelae even years after their infections. These sequelae include 
seizures, upper and lower motor neuron weakness, cerebellar and extrapyramidal signs, flexion 
deformities of the arms, hyperextension of the legs, cognitive deficits, language impairment, 
learning difficulties, and behavioral problems.13 
 
1.2.6 Therapeutics and Vaccines 
Currently, there are four different types of JEV vaccines which are available for human use 
around the world. Table 2 shows a summary for these four vaccines and illustrates the 
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differences between vaccine type, JEV strain used, and the vaccine name.12 Of these four 
vaccines only two are approved for use in humans within the United States, the inactivated 
mouse brain--derived vaccine (JE-VAX [JE-MB]) and an inactivated Vero cell culture-derived 
vaccine (IXIARO [JE-VC]).13 The JE-MB vaccine has been licensed for use in the United States 
since 1992 and is occasionally recommended for travelers aged ≥1 year who plan to travel to 
JEV endemic regions.13 Due to the fact that several effective vaccines are available in Asia for 
human use, efficacy trials that randomized and controlled would not be ethically responsible and 
logistically difficult. The JE-VC vaccine was licensed based off of its ability to elicit JEV-
specific neutralizing antibodies, which studies have shown to be a reliable evaluation of 
efficacy.13 Although there are multiple vaccines available for human use, it is unlikely that the 
entire at-risk population will be vaccinated, and even though the vaccines have greatly reduced 
the JEV disease prevalence, only approximately 80% protective efficacy has been demonstrated. 
Therapeutic options for treatment of JE consists of only supportive care and management of 
clinical complications, and no specific antiviral medications have been developed to treat the 
severe forms of JEV disease.13 In controlled clinical trials, corticosteroids, interferon-alpha-2a, 
and ribavirin were tested, but failed to improve the clinical outcome.13 Due to these factors, it is 
clear that development of effective therapies against severe forms of JEV disease should be a 
research priority to address this public health concern.  
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Table 2: Summary of 4 different types of JEV vaccines12 
 
1.3 Alpha-macroglobulins: 
 
1.3.1 Human alpha-macroglobulins 
Alpha-macroglobulins are an integral part of host innate immunity and for this reason these large 
glycoproteins have been evolutionarily conserved among invertebrates and vertebrates alike.14 
Proteins included in the alpha-macroglobulin family are the alpha-1-macroglobulin (A1M), 
alpha- 2-macroglobulin (A2M), complement components (C3, C4, and C5), and pregnancy zone 
protein.14 For the case of A2M, it can function as an antiproteinase and is present in high 
abundance in human plasma, anywhere from 2 – 4 mg/mL, and factors such as the individuals 
diet, as well as other disease and immune status related factors such as diabetes can account for 
this variation.14 Human A2M can be classified as a homotetramer, meaning the protein is made 
up of four identical subunits, which are bound together by a non-covalent association of two 
disulphide-bonded pairs of subunits.14 Human A2M is unique in its function in that it can inhibit 
virtually any proteinase present in plasma, as well as from proteinases from other sources, but it 
also functions as the delivery vehicle of proteinases to an endocytic proteinase clearance 
pathway.14 These alpha-macroglobulins are mainly synthesized within the liver; however, they 
are also locally synthesized by many important cell types in the context of WNV disease and 
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WNVND such as macrophages, fibroblasts, and cell populations within the brain tissue.14 Figure 
9 shows a diagram of the mechanism that allows the A2M protein to entrap proteinases; up to 
two small proteinases per subunit or one large proteinase per subunit can be entrapped.14 A2M 
can also bind to many other proteins, and overall functions as an immune-regulatory protein by 
binding and shuttling pro-inflammatory cytokines and chemokines during the host inflammatory 
response.14 Again in the context of WNV disease, human A2M has been shown to bind to 
neurotrophic factors; and these neurotrophic factors are responsible for promoting neuron 
survival, maintenance and development of neurons, as well as the maintenance of neuronal 
homeostasis in response to injury.14 It is clear that human alpha-macroglobulins have many 
function throughout the body in various tissues, and Table 3 and Figure 10  highlight some of 
these functions of A2M.15,16 A2M is known to bind to the low-density lipoprotein (LDL) 
receptor related protein, or LRP, and this receptor is present on many cell types throughout the 
body.15 Due to the previously stated factors, examination of A2M in the context of WNV disease 
is warranted.  
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Figure 9: Model of Human A2M14 
 
 
Figure 10: The heterogeneity of binding partners (white circles) and functions of α2M16 
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Table 3: Comparison of α2-macroglobulin with active site protease inhibitors15 
 
1.3.2 Mouse alpha-macroglobulins 
Overall much less is known about mouse alpha-macroglobulins; however, it is known that there 
are two main mouse alpha-macroglobulins present in the plasma of mice and these are known as 
PZP, formerly termed mouse alpha-2-macroglobulin (MA2M), and murioglobulin-1 (MUG-1).14 
PZP is a tetrameric protein and a close homologue of human A2M, and like human A2M the 
mouse PZP protein is highly expressed within the liver of adult mice.17 On the other hand, MUG-
1 is a single chain proteinase inhibitor and is primarily identified in the plasma of mice, and is 
similarly present at high concentrations from anywhere between 1 – 2 mg/mL.14 Human A2M 
and mouse PZP are comparable in the sense that they share broad proteinase-inhibitory 
specificities and undergo equivalent proteinase-induced conformational changes.17 An alpha-
macroglobulin deficient mouse model has been created, and these alpha-macroglobulin mice 
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develop normally and are fertile. Interestingly, the alpha-macroglobulin deficient mice have been 
reported to respond differently than a comparable wild-type mouse when challenged with certain 
exogenous agents and have shown increased resistance to the lethal effects of endotoxins.17 The 
inhibition of proteinases functionality of mouse PZP and MUG-1 have been shown to be 
partially redundant, however the growth factor carrier activities of these proteins are 
independent. During pregnancy an increased level of MUG-1 has been reported to be present in 
wild type mice, and this suggests that it plays a role in the immunological state during 
pregnancy.17 In another mouse study it has been shown that treatment with mouse PZP via 
microparticles protected mice from sepsis, preserved neutrophil chemotactic responses in the 
presence of endotoxin, and stimulated bacterial phagocytosis as well as reactive oxygen species 
(ROS) production via its receptor LRP1.18  
 
1.3.3 Alpha-macroglobulins and diseases 
Alpha-macroglobulins have been shown to have important roles in the host immune regulation 
but have also been shown to play an important role in the context of certain infectious and 
immunological diseases. After parasitic infection with Trypanosoma cruzi, or T. cruzi, it has 
been shown that A2M can regulate cellular apoptosis that is triggered by the infection and can 
limit the generation of hydrogen peroxide (H2O2) from polymorphonuclear leukocytes, as well as 
clear unfolded and misfolded proteins in extracellular spaces as a result of the infection.14 
Likewise, A2M can bind endotoxins produced during bacterial infections and can protect tissues 
within the body from the harmful effects of the endotoxins.14 A2M has been shown to bind viral 
particles and allow for uptake of the virus into host immune cells such as macrophages, as well 
as antigen presenting cells. In this sense A2M helps to bridge the gap between the innate and 
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adaptive responses of the host immune system in the acute phase of viral infections.19 In the case 
of disease as a result of immunological dysregulation, A2M can be considered a diagnostic 
marker for several disease processes such as liver fibrosis, cardiac hypertrophy, differentiating 
myocardial infarcted diabetic patients from diabetic patients without myocardial infarction, and 
HIV with cardiac manifestations.14 In the context of human neuronal diseases, which again 
highlights the important of the role of A2M in WNVND, A2M has also been characterized as a 
marker for preclinical Alzheimer’s disease (AD) which reflects neuronal injury in these 
individuals.20 On the other hand, A2M has been tested as a vaccine adjuvant and may be a 
beneficial antigen delivery system for the formulations of vaccines to promote a greater adaptive 
immune response, as well as a drug delivery system.14  
 
 
Table 4: Role of α2M in various pathophysiological conditions14 
 
Human A2M can be used as a marker in the diagnosis and prognosis in a number of disease 
processes, and in the case of liver fibrosis the use A2M as a clinical biomarker for disease may 
be a substitute for the standard risky and invasive procedure of a liver biopsy.14 The serum 
concentration of A2M changes during the process of liver fibrosis and observation can be used to 
indicate the stage of damage and disease progression in the liver in Hepatitis C infection.14 The 
cardiac isoform of human A2M in serum can be used as an early marker in cardiac hypertrophy 
and ventricular mass, and in diabetic patients this can also be used as a diagnostic marker for 
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myocardial infarction.14 Likewise, the cardiac isoform of A2M in serum has also been shown to 
be a clinical biomarker for the onset and presence of heart disease such as ventricular septal 
defect, atrial septal defect, aortic regurgitation, aortic stenosis etc., resulting from abnormal left 
ventricular hypertrophy in HIV infected patients.21 Patients who have undergone distal or total 
gastrectomy for the treatment of gastric cancer have been shown to have significantly higher 
concentrations of A2M in their blood.14 In pancreatitis, the amount of complexed A2M has been 
shown to increase with the severity of the attack, and in the case of Inflammatory Bowel Disease 
(IBD) A2M is excreted in high concentrations and this also has the potential to be used as a 
clinical diagnostic biomarker.14 The concentration of A2M, as well as myeloperoxidase and C-
reactive protein, can be measured in urine and provides a non-invasive differential diagnostic 
tool for renal graft dysfunction.14 A2M and A2M-proteinase complexes have also been employed 
in clinical use as a functionally relevant biomarker in the male genital tract secretion for prostate 
complications.14 In the consideration of thrombosis for patients who have deficiency of 
antithrombin III (AT III), A2M is able to prevent thrombosis from occurring in children because 
they express A2M at higher levels than adults, which puts adults at a greater risk. Therefore 
A2M has the potential to be used as a clinical treatment in adult AT III deficient patients 
experiencing thrombosis.14 A2M isolated from the synovial fluids in patients suffering from 
Rheumatoid Arthritis (RA) has been shown to be oxidized seven fold higher than healthy 
controls, and has a potential to be used as a clinical biomarker in the disease process of RA as 
well.22 Other studies have shown that serum levels of A2M are significantly increased in patients 
who have suffered an ischemic stroke, and that there are strong correlations between 
concentrations of A2M in the blood and white matter lesions (WML).23 WML are known to be 
associated with aging and ventricular risk factors, and the development of WML is known to be 
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a causative agent of cognitive impairment, dementia, and disability.23 Along the same lines, 
A2M within the brain of Alzheimer’s dementia (AD) affected patients has been identified as a 
genetic risk factor and it is thought that an increased amount of A2M within the brain of these 
AD affected patients leads to neurotoxicity and increased disease progression.24  
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Objective, Hypothesis and Rationale:  
The objective of this study is to define the function of a-macroglobulins in the replication and 
pathogenesis of WNV and JEV, using a mouse model. Our central hypothesis is that a-
macroglobulins facilitate entry of flavivirus in myeloid cells, the first cells the virus encounter, 
leading to high viremia and virus entry in to the brain. The overall rationale is that high peripheral 
viremia during WNV and JEV infections results in high brain viral load, thereby leading to severe 
encephalitis. It is known that a-macroglobulins can bind and internalize virus protein into the cells. 
Moreover, gamma globulins (immunoglobulins) dependent enhancement of flavivirus infection is 
well known. In vivo loss of function experiments using PZP-/-/MUG1-/- mice [hereafter, double 
knockout (DKO)] model will allow us to demonstrate the in vivo role of a-macroglobulins after 
virus infection. We expect that decrease in initial infection (viremia) will lead to a reduced virus 
entry in the brain, resulting in improved overall survival in the a-macroglobulins deficient mice 
when compared to wild-type mice.  
 
Innovation and Significance: 
Although a-macroglobulins are known to bind and internalize viral proteins and modulate the 
immune response, their in vivo function in viral infections has yet to be defined. The proposed 
research is highly innovative as this study will be the first to characterize the function of a-
macroglobulins in the pathogenesis of WNV- and JEV-associated encephalitis. Our study supports 
a novel concept that a-macroglobulins enhance viral infection in vivo. Currently, a-macroglobulin 
immune therapy is used in the clinical setting for treatment of disease such as arthritis and a-2-
macroglobulin is used as a disease marker for liver fibrosis. Overall, our study will provide new 
insight into a novel host factor for flavivirus replication and dissemination, and thus will have a 
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significant impact on the development of much-needed therapeutic interventions that will reduce 
virus spread and improve disease outcome.  
 
Specific Aims: 
Specific Aim 1: Determine the role of a-macroglobulins in WNV and JEV disease progression 
and outcome in mice.  
1.1) Examine the survival pattern and clinical signs of wild-type (WT) and DKO mice after 
subcutaneous inoculation with WNV. 
1.2) Examine the survival pattern and clinical signs of WT and DKO mice after subcutaneous 
inoculation with JEV. 
Specific Aim 2: Determine the role of a-macroglobulins in virus replication and anti-viral 
response in mice after WNV infection.   
2.1) Analyze the kinetics of WNV replication in the serum, peripheral organs (spleen, kidneys) 
and brain of WT and DKO mice. 
2.2) Analyze the anti-viral responses, including interferon and antibody response, in WNV-
infected WT and DKO mice.   
 
Specific Aim 3: Examine WNV-induced peripheral- and central -nervous system inflammation in 
WT and DKO mice.  
3.1) Analyze the protein levels of pro-inflammatory cytokines/chemokines in serum, spleen and 
brain of WNV-infected WT and DKO mice. 
3.2) Analyze the mRNA levels of key CNS genes including anti-viral, inflammatory and apoptotic 
genes in the brains of WNV-infected WT and DKO mice. 
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Abstract 
West Nile virus (WNV) and Japanese encephalitis virus (JEV) are the leading causes of arboviral 
encephalitis in humans. No effective therapies exist for treating individuals with encephalitic 
flavivirus infections. a--macroglobulins are physiological proteinase inhibitors with important 
roles in inflammation and immune modulation. In mice, two main a-macroglobulins are present 
as plasma proteins, pregnancy zone protein (PZP) and murinoglobulin-1 (MUG). We have 
previously reported that WNV infection induced upregulation of a-macroglobulins in mice. To 
define the role of a-macroglobulins in flavivirus infection in vivo, we investigated the 
susceptibility of mice deficient in a-macroglobulins (PZP and MUG-1 double knockout; DKO) 
against lethal dose of WNV or JEV. We found that DKO mice were completely resistant to lethal 
WNV and JEV encephalitis, suggesting that a-macroglobulins play a deleterious role in 
flavivirus infection. Increased survival in WNV-infected DKO mice was associated with 
significantly reduced viral burden in serum, spleen, kidney and brain compared to wild-type 
(WT) mice. Moreover, levels of cytokines and chemokines in the serum, spleen and brain were 
significantly reduced in WNV-infected DKO mice compared to WT mice. Collectively our data 
demonstrate that a-macroglobulins contribute to the pathogenesis of flavivirus encephalitis in 
mice.  
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Background 
 
Members of the Flavivirus genus are the leading causes of epidemic encephalitis worldwide and 
continue to spread globally. Since its initial introduction into New York in 1999, West Nile virus 
(WNV), a NIAID Category B Priority Pathogen, has become the leading cause of arboviral 
encephalitis in the United States, resulting in hundreds of deaths5,9,25. Similarly, Japanese 
encephalitis virus (JEV) is the primary cause of viral encephalitis in Asia, accounting for around 
50,000 cases per year and an estimated 10,000 deaths, with long-term neurologic sequelae in about 
one-half of the survivors. JEV also affects U.S. travelers and U.S. military personnel deployed 
overseas12. WNV and JEV continue to spread and cause human disease in new areas of the world. 
Currently, no effective therapies exist for treating individuals with encephalitic flavivirus 
infections, and the disease pathogenesis is not completely understood9,12.  
 
a-macroglobulins are physiological proteinase inhibitors with important roles in inflammation 
and immune modulation14. a-macroglobulins are mainly produced by the liver, and also locally 
synthesized by macrophages, fibroblasts, and brain cells14. In human, two main α-
macroglobulins are present as plasma proteins, α-2-macroglobulin (A2M) and pregnancy zone 
protein (PZP)26. A2M, a key member of the alpha macroglobulin superfamily, is a high-
molecular weight homotetrameric glycoprotein. A2M is one of the most abundant protein in 
human plasma with a concentration of 2–4 mg/mL of plasma14. A2M is a major player involved 
in the binding and shuttling of protease inhibitors, growth factors, cytokines, hormones, disease 
factors, and various small molecule nucleophilic ligands14,22,27. Upregulation and/or 
downregulation of A2M in circulation and extravascular space have been linked to 
immunological abnormalities, tissue inflammation, Alzheimer disease, and numerous cytokine-
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related diseases14,22,24,28. In several instances, A2M has proven exceedingly useful as a direct 
clinical biomarker for numerous disorders such as inflammatory bowel disease, myocardial 
infarction, stroke, and Hepatitis C virus associated-liver fibrosis21,23,29-31. In adult mice, two main 
a-macroglobulins are present as plasma proteins, PZP and murinoglobulin-1 (MUG-1)14. Like 
human A2M, mouse PZP is highly expressed in the liver of adult mice32. MUG-1 is a single 
chain proteinase inhibitor, which is also found at high concentrations in adult murine plasma (1–
2 mg/mL)27,32,33.  
 
Human A2M is known to bind and enhance internalization of different toxins and pathogens 
such as bacteria or virus34. Viral proteins conjugated to A2M are taken up by antigen presenting 
cells more effectively than the free viral proteins35. It has been demonstrated that A2M binds to 
DENV virions of all four serotypes and enhances DENV-2 infectivity in vitro36. It has also been 
shown that HIV-1 envelope protein conjugated to A2M is effectively taken up by macrophages, 
which results in an increased production of specific antibodies against the peptide34,37. Similarly, 
A2M-antigen complexes of hepatitis B surface antigen also produce antibody responses in mice 
that are four to five orders of magnitude greater than those elicited by antigen alone38. In addition 
to antibody response, antigen delivery by A2M enhances the cytotoxic T lymphocyte response 
and production of inflammatory cytokines and chemokines39,40. Therefore, A2M packaging has 
been proposed as a valuable approach to develop a faster immune response with fewer doses of 
vaccine35.  
 
Although A2M is known to bind and internalize viral proteins and modulate immune response, 
and has been demonstrated to enhance virus infectivity in vitro, its in vivo function in viral 
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infection has yet to be defined. We have previously reported that WNV infection induced 
upregulation of a-macroglobulins in mice41. To define the in vivo role of a-macroglobulins in 
flavivirus infection, we investigated the susceptibility of mice deficient in a-macroglobulins 
(PZP and MUG-1 double knockout) against lethal dose of WNV or JEV. Our results demonstrate 
conclusively that a-macroglobulins promote virus replication, tissue tropism and inflammatory 
response, thereby enhancing disease severity. 
 
Results 
α-macroglobulins deficiency confers resistance to lethal WNV and JEV infection:  
We inoculated C57BL/6J (WT) and mice deficient in PZP and MUG-1 (hereafter referred as; 
double knockout mice or DKO) with 100 plaque-forming units (PFU) of WNV via subcutaneous 
route. Animals were monitored daily for clinical signs and mortality. As expected, WT mice 
began to demonstrate clinical signs at day 6 after inoculation and exhibited high mortality (41%). 
In comparison, all DKO mice survived, suggesting a detrimental role for α-macroglobulins 
during WNV infection (Fig. 1A). As depicted in Fig. 1B, both WT and DKO mice demonstrated 
clinical evidence of infection characterized by ruffled fur and hunchbacked posture, however, 
severe neurological symptoms such as paresis, hind limb paralysis, tremors and ataxic gait were 
observed only in WT mice. The difference in morbidity and mortality between WT and DKO 
mice infected with was statistically significant. All surviving animals were positive for anti-
WNV neutralizing antibodies, confirming virus infection. 
 
Next, we inoculated C57BL/6J (WT) and DKO mice with 10,000 PFU of JEV via subcutaneous 
route. Animals were monitored daily for clinical signs and mortality. As expected, WT mice 
 
 
33 
began to demonstrate clinical signs at day 7 after inoculation and exhibited high mortality (30%). 
In comparison, all DKO mice showed reduced sign of morbidity and no mortality, suggesting α-
macroglobulins modulated the infectivity of JEV (Figs. 1C and 1D). The difference in morbidity 
and mortality between WT and DKO mice infected with JEV was statistically significant.  
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Figure 1 
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Figure 1. Survival analysis and clinical score of WT and DKO mice following WNV and 
JEV infection. (A) Eight-week old C57BL/6J WT and DKO mice were inoculated 
subcutaneously with 100 PFU of WNV. All mice were observed for 21 days. Data are combined 
from two independent experiments (n = 22 mice per group). The survival difference between WT 
and DKO mice was statistically significant. (B) Animals were monitored for clinical scores twice 
a day. The designation for the clinical scores is as follows: 1, ruffled fur/hunched back; 2, 
paresis/difficulty walking; 3, paralysis; 4, moribund/euthanized; and 5, dead. (C) Eight-week old 
C57BL/6J WT and DKO mice were inoculated subcutaneously with 10,000 PFU of JEV. All 
mice were observed for 21 days. Data are combined from two independent experiments (n = 18 
mice per group). The survival difference between WT and DKO mice was statistically 
significant. (D) Animals were monitored for clinical scores twice a day as described above. Error 
bars represent SEM. *p < 0.05, **p < 0.001. 
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α-macroglobulins modulate WNV replication, tissue tropism, and neuroinvasion: To better 
understand how α-macroglobulins mediate WNV pathogenesis, we measured viral load in the 
serum, spleen, kidney and brain of the WT and DKO mice at various time points after WNV 
inoculation. Consistent with the survival result, WNV titers in the serum were significantly lower 
in DKO mice when compared to WT mice at both days 2 and 4 after inoculation (Fig. 2A). The 
virus was cleared from the serum of all infected mice by day 8 after inoculation. Virus titers 
assayed in the spleen also followed a similar trend, and DKO mice spleens had significantly 
lower virus titers than WT mice at both days 2 and 4 after inoculation (Fig. 2B). Virus 
replication kinetics observed in the kidneys of WT and DKO mice was similar to the spleen (Fig. 
2C). We next measured virus titers in the brains at days 2, 6, and 8 after inoculation. WNV is 
typically detected in the CNS of mice between 4 and 6 days after WNV inoculation via the 
subcutaneous route. Consistent with this trend, WNV was not detected in the brains of both WT 
and DKO mice at day 2 after inoculation (Fig. 3A). High viral load was detected in the brains of 
86% of the WT mice at day 6 after inoculation by plaque assay. In comparison, WNV was 
detected in only 50% of the DKO mice at day 6 after inoculation. Similarly, at day 8 after 
inoculation, high viral load was detected in all of the WT mice. However, WNV was detected in 
only 50% of the DKO mice at day 8 after inoculation. WNV titer was significantly higher in WT 
mice than in DKO mice at day 8 after inoculation (Fig. 3A). We also measured WNV RNA 
copies in the brains of WT and DKO mice. Similar to plaque assay, WNV RNA was 
significantly higher in WT mice than in DKO mice at days 6 and 8 after inoculation (Fig. 3B). 
These data indicate that α-macroglobulins facilitate WNV replication, tissue tropism and 
neuroinvasion.  
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Figure 2 
A B  
 
C  
 
Figure 2. Viral burden in the serum and peripheral tissues of WT and DKO mice. Eight-
week old C57BL/6J WT and DKO mice were inoculated subcutaneously with 100 PFU of WNV, 
and viral loads were measured in the (A) serum, (B) spleen, and (C) kidney at indicated time-
points by plaque assay. The data are expressed as PFU/mL of serum and PFU/g of tissue. Each 
data point represents an individual mouse, and data from two independent experiments are 
depicted. The data for mock-inoculated mice were negative for WNV and are not depicted on the 
graphs. Data points below the horizontal dotted line are negative. The solid horizontal line 
signifies the median of 6 to 15 mice per group. *p<0.05.  
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Figure 3 
A B  
 
 
Figure 3. Brain viral load in WT and DKO mice. Eight-week old C57BL/6J WT and DKO 
mice were inoculated subcutaneously with 100 PFU of WNV. (A) Viral loads were measured in 
the brains at indicated time-points by plaque assay. The data are expressed as PFU/g of tissue. 
Each data point represents an individual mouse, and data from two independent experiments are 
depicted. The data for mock-inoculated mice were negative for WNV and are not depicted on the 
graphs. Data points below the horizontal dotted line are negative. The solid horizontal line 
signifies the median of 6 to 7 mice per group. *p<0.05. (B) WNV copy number in the brain was 
determined by qRT-PCR. The data are expressed as genome copies/µg of RNA. Error bars 
represent SEM (n = 6-7 mice per group). *p<0.05. 
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Antiviral immune responses in WT and DKO mice:  
Humoral immunity is an essential component of the immune response to WNV infection. The 
induction of anti-WNV neutralizing antibody is essential for suppressing viremia and virus 
dissemination1. Therefore, we examined titers of anti-WNV neutralizing antibodies in the serum 
of WT and DKO mice using PRNT. WNV infection elicited robust neutralizing antibodies in 
both WT and DKO mice. Consistent with previous studies, anti-WNV neutralizing antibody was 
first detected by day 6 after inoculation and gradually increased at day 8 after inoculation (Fig. 
4A). Titers of neutralizing antibodies were comparable in both WT and DKO mice.  
 
Antiviral type I interferon (IFN-a and b) production is essential in suppressing viral titers in the 
periphery and the brain1. Therefore, we measured the levels of IFN-a in the serum and brain of 
WT and DKO mice. High levels of IFN-α were detected in the serum of WT mice at day 2 after 
inoculation, which then decreased at day 6 after inoculation. In contrast, DKO mice did not elicit 
strong IFN response at day 2 after inoculation, which was significantly low in comparison to WT 
mice (Fig. 4B). We next examined IFN-α and IFN-b levels in the brains at days 6 and 8 after 
inoculation. In the brain, WT mice developed a detectable interferon response at day 6 after 
inoculation, which increased further at day 8 after inoculation. Similar to serum, DKO mice did 
not elicit a strong IFN response in the brain and levels of IFN-α and IFN-β were significantly 
low in comparison to WT mice at day 8 after inoculation (Fig. 4C and 4D).  
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Figure 4 
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Figure 4. WNV-specific immune responses in WT and DKO mice. Serum was collected from 
WT and DKO mice at indicated time points after virus inoculation. (A) Serum was serially 
diluted from 1:40 to 1:5,000 and PRNT was conducted against WNV. Data are expressed as 
mean log10 titer ±SEM and is representative of two independent experiments (n = 6-7 mice per 
group). (B) IFN-α levels were measured in the serum using mouse IFN-α ELISA kit. The data 
are expressed as the mean concentration (pg/mL) ± SEM, representing two independent 
experiments (n = 6-7 mice per group). *p<0.05. (C) IFN-α, and (D) IFN-β levels were measured 
in the brain homogenates using ELISA. The data are expressed as the mean concentration (pg/g 
of tissue) ± SEM, representing two independent experiments (n = 6-7 mice per group). *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
Peripheral cytokine responses are blunted in DKO mice:  
WNV-induced expression of pro-inflammatory cytokines such as IL-1β and TNF modulate BBB 
permeability, facilitate leukocyte trafficking into the brain, activate glial cells, and mediate 
neuronal death after infection1,42,43. It has been demonstrated that WNV-induced expression of 
chemokines such as CCL2, CCL3, CCL4, CCL5, and CXCL10 are associated with enhanced 
trafficking of leukocytes into the brain44-46. Human and murine α-macroglobulins are also 
associated with an enhanced inflammatory response to various stimuli14,33,40,47. Therefore, we 
next assessed the protein levels of these cytokines and chemokines in the serum and spleen of 
WT and DKO mice using multiplex immunoassay. Very low levels of these cytokines and 
chemokines were detected in the serum of uninfected WT and DKO mice (Mock). We did not 
observe any differences in the basal cytokine and chemokine levels in the serum from uninfected 
WT and DKO mice. As expected, WNV infection resulted in a dramatic increase in protein 
levels of multiple cytokines and chemokines in the serum of WT mice at days 2 and 4 after 
inoculation (Fig. 5). However, unlike WT mice, infected DKO mice produced significantly lower 
levels of pro-inflammatory cytokines and chemokines. The levels of interleukin (IL)-6, -10, -13, 
and M-CSF were significantly higher in WT mice than DKO mice at day 4 after inoculation. The 
level of IL-5 was significantly higher in WT mice at day 2 after inoculation whereas, the level of 
G-CSF was significantly higher in WT mice at day 8 after inoculation (Fig. 5). A similar pattern 
was also observed for chemokine expression. The levels of CXCL2 and CXCL10 were 
significantly higher in WT mice than DKO mice at day 4 after inoculation. The level of CXCL1 
was only increased significantly at day 2 after inoculation in WT mice when compared to DKO 
mice. However, the comparison of levels of serum cytokines and chemokines, such as IL-1a, 
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CCL4, and CXCL9 between both groups demonstrated no significant differences in their levels 
at any time point after inoculation (Fig. 5).  
 
Similar to serum, we did not observe any differences in the basal cytokine and chemokine levels 
in the spleens from uninfected WT and DKO mice. WNV infection resulted in a dramatic 
increase in protein levels of multiple cytokines and chemokines in the spleens of WT mice at day 
2 after inoculation (Fig. 6). However, unlike WT mice, cytokine responses were blunted in DKO 
mice. The levels of TNF-a, IFNγ, IL-6, IL-12, IL-13, IL-15, GM-CSF, LIF, CXCL10 and M-
CSF were significantly higher in WT mice than DKO mice at day 2 after inoculation. No 
significant difference was observed in the levels of IL-1a, IL-10, CCL4, CXCL2, and CXCL9 
between WT mice and DKO mice. These results demonstrate that the absence of α-
macroglobulins result in reduced systemic cytokine response to WNV infection in the periphery.  
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Figure 5 (Cytokines) 
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Figure 5 (Chemokines and Growth Factors) 
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Figure 5. Cytokines and chemokines levels in the serum of WT and DKO mice. Serum was 
collected from WT and DKO mice at indicated time points after virus inoculation. Levels of 
chemokines and cytokines as noted in the figure were measured using multiplex immunoassay 
and are expressed as the mean concentration (pg/mL) ±SEM, representing two independent 
experiments (n = 7-16 mice per group). *p<0.05.  
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Figure 6 (Cytokines) 
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Figure 6 (Chemokines and Growth Factors) 
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Figure 6. Cytokines and chemokines levels in the spleens of WT and DKO mice. Spleens 
were harvested from WT and DKO mice at indicated time points and homogenized as described 
in the materials and methods section. Levels of cytokines and chemokines as noted in the figure 
were measured using multiplex immunoassay and are expressed as the mean concentration (pg/g 
of tissue) ± SEM, representing two independent experiments (n = 6-7 mice per group). *p<0.05.  
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DKO mice exhibit reduced inflammation in the CNS: 
 We further examined the protein levels of multiple inflammatory cytokines and chemokines in 
the brain homogenates of WT and DKO mice. Very low levels of these cytokines and 
chemokines were detected in the brains of uninfected mice (mock). As expected, levels of 
multiple cytokines and chemokines increased dramatically in WT mice brains at day 8 after 
inoculation, but this increase was not observed in the DKO mice (Fig. 7). The levels of TNF-α, 
IFNγ, IL-1α, IL-1b, IL-6, IL-12 (p70), IL-13, G-CSF, and M-CSF were significantly higher in 
the brains of WT mice than DKO mice at day 8 after inoculation. Similarly, the levels of eotaxin, 
CCL2, CCL5, CXCL1, CXCL2, CXCL9, and CXCL10 were significantly higher in the brains of 
WT mice than DKO mice at day 8 after inoculation. However, the levels of IL-10 and IL-12 
(p40) did not differ between both the groups (Fig. 7).  
 
Next, we analyzed levels of mRNA from WT and DKO mouse brains at day 8 post WNV-
infection. Analysis was performed for over 1,000 different genes linked to various inflammatory 
processes using Nanostring technology and nSolver software. The top 20 up-regulated genes in 
WT mice at 8 days post infection is shown in table 1. A consistent trend with our previous data is 
seen where mRNA levels in WT mice are drastically elevated at this time point post infection 
and comparing DKO mice to WT shows a significant decrease in mRNA levels in DKO animals. 
Overall mRNA fold changes are calculated compared to mock-infected controls.  
 
Finally, further utilization of Nanostring technology and nSolver software allowed for the 
generation of multiple heatmaps corresponding to different immune pathways in response to 
WNV infection. Figure 8 demonstrates the levels of mRNA present for genes correlating to 
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pathogen response in the brains of WT, DKO, and mock-infected control animals 8 days post 
infection.  
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Figure 7 (Cytokines) 
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Figure 7 (Chemokines and Growth Factors) 
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Figure 7. Cytokines and chemokines levels in the brains of WT and DKO mice. Brains were 
harvested from WT and DKO mice at indicated time points and homogenized as described in the 
materials and methods section. Levels of cytokines and chemokines as noted in the figure were 
measured using multiplex immunoassay and are expressed as the mean concentration (pg/g of 
tissue) ± SEM, representing two independent experiments (n = 6-7 mice per group). *p<0.05, 
**p<0.0001.  
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Table 1 
 
Gene Name C57BL/6J A2M -/- 
Cxcl10 646.55 8.55 
Il1rn 527.01 8.02 
Cxcl9 289.1 12.92 
Ifi44 242.1 5.06 
Ccl2 241.92 5.57 
Rsad2 170.64 4.92 
Isg15 151.73 4.4 
Usp18 144.77 5.09 
Oasl1 139 4.44 
Zbp1 136.25 4.89 
Gzmb 132.16 4.87 
Irf7 131.46 4.44 
Ifit1 122.14 3.57 
Ccl5 113.9 4.83 
Cfb 101.36 3.56 
Ifit3 89.83 3.73 
Ccl12 88.13 5.18 
Bst2 84.25 4.01 
Ccl3 68.59 3.88 
Nlrc5 63.42 2.98 
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Table 1. Top 20 up-regulated Immune-related Genes in WT mice 
C57BL/6J WT mice and DKO mice were inoculated subcutaneously with 100 PFU of WNV and brains 
were harvested 8 days post infection. Brains were homogenized, and RNA extraction was performed on 
the brain homogenate as previously described. RNA was given to the UH Manoa Cancer Center for 
miRNA Nanostring analysis. Similarly, mock-infected controls were euthanized 8 days post mock-
infection and brains were harvested and homogenized prior to RNA extraction.  
*mRNA fold change relative to mock-infected controls 
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Figure 8 
 
*Immune genes to pathogen response 
 
Figure 8. Heatmap of Immune-related genes to Pathogen Response 
C57BL/6J WT mice and DKO mice were inoculated subcutaneously with 100 PFU of WNV and brains 
were harvested 8 days post infection. Brains were homogenized, and RNA extraction was performed on 
the brain homogenate as previously described. RNA was given to the UH Manoa Cancer Center for 
miRNA Nanostring analysis. Similarly, mock-infected controls were euthanized 8 days post mock-
infection and brains were harvested and homogenized prior to RNA extraction. Further statistical analysis 
and generation of heatmaps was performed using nSolver software. The above heatmap was generated for 
genes corresponding to pathogen response.  
*mRNA fold change relative to mock-infected controls 
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Discussion 
In this study, we demonstrate that α-macroglobulins enhance WNV and JEV infection in vivo. 
PZP-/-/MUG1-/- mice (DKO mice) demonstrated complete resilience to subcutaneous lethal WNV 
and JEV infection and reduced viral burden in serum, spleen, kidney and brain. These 
observations were associated with significantly attenuated inflammatory responses in the 
periphery and the brain of DKO mice.  
 
In adult mice, two main a-macroglobulins are present as plasma proteins, PZP (formerly termed 
‘mouse A2M’ or MAM) and MUG-114,27,32. Therefore, in this study we used mice deficient in 
both PZP and MUG-1. This mouse model has been previously used to understand the role of α-
macroglobulins in acute pancreatitis, Trypanosoma cruzi infection, and drug pharmacokinetics48-
50. In our study, DKO mice exhibited significantly lower levels of virus titers in the serum, which 
correlated with decreased tissue tropism as compared to WT mice. It is known that high viremia 
during WNV infection results in high brain viral load in mice, thereby leading to severe 
encephalitis51,52. WT mice displayed significant virus replication in peripheral tissues such as 
spleen and kidney compared to DKO mice. Similar to the periphery, there was reduced virus 
replication in the brains of DKO mice leading to increase survival. This is in agreement with 
previous observations showing that a-macroglobulins deficient mice had significantly lower 
parasitemia than in WT mice after infection with T. Cruzi48. It has also been demonstrated that 
a-macroglobulins deficient mice are resistant to the lethal effects of LPS33,47. Similarly, mice 
deficient in a-macroglobulins are also resistant to lethal infection by Klebsiella pneumoniae and 
had significantly less bacteria in the blood and in different organs than in WT mice53.  
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Viral proteins conjugated to A2M are taken up by antigen presenting cells more effectively than 
the free viral proteins34. Therefore, A2M has been used as an adjuvant/delivery protein to 
enhance the weak immunogenicity of subunit vaccines35,37. A2M has been shown to interact with 
the envelope protein of dengue virus and enhances virus infectivity in vitro36. Similarly, it has 
been shown that A2M binds to HSV-1 particles and facilitates internalization of HSV resulting in 
increase in the synthesis of viral proteins in the neuronal cell line54. A2M binds to its specific 
receptor on the cell surface of many cell types14,55. It is possible that A2M facilitates 
internalization of WNV through the low-density lipoprotein (LDL) receptor related protein 
(LRP), a heterodimer glycoprotein and receptor of A2M55. HCV and other members of 
Flaviviridae are endocytosed via the LDL receptor56. It has been demonstrated that binding of 
HIV-1 transactivator (Tat) protein to LRP promotes efficient uptake of Tat into neurons57. Future 
studies are warranted to delineate the potential role of A2M as a shuttle for WNV to LRP as a 
receptor complex that may mediate virus endocytosis.  
 
A2M binds to several important cytokines, including basic fibroblast growth factor, platelet-
derived growth factor, interleukins, TNF and modifies their biological activity14. The exact role 
of the interaction with these non-proteolytic proteins remains unknown. WNV-induced pro-
inflammatory cytokines and chemokines are known to modulate BBB permeability, activate glial 
cells, and mediate neuronal death, leading to the induction of lethal encephalitis1,42,43. In this 
study, we demonstrate significantly elevated levels of cytokines such as IL-1β, IL-6, TNF, IL-1α, 
and IFN-γ in the serum, spleen and brain of WT mice after WNV infection, which correlated 
with increased level of WNV observed in these mice. In contrast, absence of α-macroglobulins 
results in reduced cytokine response to WNV infection in the periphery and brain. This data is 
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consistent with previous observations that mice deficient in α-macroglobulins demonstrate an 
attenuated inflammatory response to various stimuli such as T. cruzi, in which a heightened 
inflammatory response was correlated with increased disease severity47,48,50. Murine α-
macroglobulins are essential for the normal development of fever and inflammation in response 
to bacterial endotoxin33,47. It has been demonstrated that murine α-macroglobulin contributes to 
TNF-induced lethal inflammatory shock in mice58. Also, human and murine α-macroglobulins 
are able to induce prostaglandin E2 and nitric oxide synthesis33. Therefore, it is possible that 
increased cytokine and chemokine responses in the presence of α-macroglobulins may contribute 
to severe WNV disease severity.  
 
In conclusion, our data for the first time demonstrate the critical role of α-macroglobulins during 
flavivirus infection. a-macroglobulins promote WNV replication, tissue tropism and 
inflammatory response, thereby enhancing WNV disease severity. Future studies are warranted 
to understand the mechanisms underlying the role of a-macroglobulins in flavivirus 
pathogenesis. 
 
Materials and Methods 
 
Animals: C57BL/6 J (WT) mice and PZP-/-/MUG1-/- mice (DKO mice) on C57BL/6J genetic 
background were purchased from The Jackson Laboratory (Bar Harbor, Maine, United States). 
This study was approved by the University of Hawaii Institutional Animal Care and Use 
Committee (IACUC) (protocol number 15-2202), and conducted in strict accordance with 
guidelines established by the National Institutes of Health and the University of Hawaii IACUC. 
All animal experiments were conducted in consultation with veterinary and animal care staff at 
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the University of Hawaii in animal biosafety level-3 laboratory, and mice that exhibited severe 
disease were euthanized to limit suffering. The animal suite was maintained at 720F, 45% 
humidity and on 12/12-light/dark cycle. Sawdust bedding was provided along with paper towel.  
 
WNV infection experiments and plaque assay: For survival studies, WT and DKO mice were 
inoculated subcutaneously via the footpad route with 100 plaque-forming units (PFU) of WNV 
or 10,000 PFU of JEV, and the disease symptoms and mortality were observed for 21 days as 
described previously59,60. Clinical symptoms were observed twice a day. These symptoms 
included ruffled fur, hunchbacked posture, difficulty walking, hind limb paralysis, tremors and 
ataxic gait. To limit suffering animals displaying severe symptoms such as tremors and ataxic 
gait, were euthanized immediately using CO2. On specific days after inoculation, 100 µL blood 
was collected from the tail vein, and serum was separated and frozen at −80°C for further 
analysis. 
 
In a separate set of experiments, WT and DKO mice were inoculated with PBS or 100 PFU of 
WNV, and at days 2, 6, and 8 after inoculation, mice were anesthetized using isoflurane and 
perfused with PBS. Spleen, kidneys, and brain were harvested, and flash frozen in 2-
methylbutane (Sigma). Tissues were weighed and homogenized in a bullet blender (Next 
Advance) using glass or zirconium beads. WNV and JEV titers in the serum and tissue 
homogenates were measured by plaque assay using Vero cells61,62.  
 
qRT-PCR: One half of the frozen brain tissues were powdered over dry ice to obtain a 
homogenous sampling and an aliquot of the frozen brain powder was used to extract total RNA. 
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Virus titers were analyzed in the brain by qRT-PCR as described previously. qRT-PCR was 
conducted using primers and 6-carboxyfluorescein (FAM)- and 6-carboxytetramethylrhodamine 
(TAMRA)-labeled probes specific for the WNV envelope region, and the standard curve was 
generated using RNA extracted from previously titrated WNV dilutions as described 
previously59,63.  
 
Plaque Reduction Neutralization Test (PRNT): The titers of anti-WNV neutralizing 
antibodies were measured in the serum using PRNT assay as described previously51,60,64. Serum 
collected from WT and DKO mice were serially diluted from 1:40 to 1:5000 and PRNT was 
conducted against WNV. The highest dilution of serum resulting in 80% reduction in the number 
of plaques compared to the growth of the virus control was determined. 
 
Measurement of cytokines and chemokines: The levels of cytokines and chemokines were 
measured in the serum, spleen homogenates, and brain homogenates by multiplex immunoassay 
using MILLIPLEX MAP Mouse Cytokine/Chemokine kit (Millipore) as described 
previously61,65,66. 
 
Interferon ELISA: The levels of IFN-α and IFN-β were measured in the serum and brain 
homogenates using the VeriKineTM Mouse Interferon-α ELISA Kit and VeriKineTM Mouse 
Interferon-β ELISA Kit (PBL Interferon Source) as described previously61.  
 
Statistical analysis: Log-rank (Mantel-Cox) Test and Gehan-Breslow-Wilcoxon Test were used 
to analyze survival data. Mann-Whitney test and unpaired student t-test using GraphPad Prism 
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5.0 was used to calculate p values of difference between viral titers and immune responses, 
respectively. Differences of p < 0.05 were considered significant. 
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4.1 Summary: 
West Nile virus (WNV) and Japanese Encephalitis virus (JEV) are leading causes of arboviral 
encephalitis worldwide, and WNV accounts for hundreds of deaths each year in the US alone.4,6 
The epidemiological data compiled shows that although these viruses are closely related 
flaviviuses, they are circulating within different geographical regions and the highest at risk 
populations for severe complications due to infection differ between WNV and JEV as well.6,12 
Currently, there are no clinically approved therapies for the most severe forms of the diseases 
associated with WNV and JEV, therefore studies that provide novel insights in the host factors 
that play a role in viral pathogenesis and disease progression are of utmost importance. Results 
of our studies have demonstrated for the first time the crucial role that alpha-macroglobuins play 
in WNV and JEV infections and disease progression in vivo. This was demonstrated in alpha-
macroglobulin deficient double knockout mice which have been genetically altered to allow for 
the absence of alpha-macroglobulins. The overall summary and trend of our study shows that 
WT mice demonstrated a significant amount of mortality and clinical disease after lethal 
subcutaneous WNV and JEV infections. When compared to WT, the DKO mice demonstrated 
complete resilience to these infections (100% survival) over multiple independent experiments 
and in a similar trend showed a significantly milder clinical disease as well. Viral load and 
inflammatory responses were analyzed in the periphery and multiple tissues, including the brain, 
and similar to the survival and clinical disease outcomes data the WT mice show a high viral 
burden and elevated inflammatory responses in these tissues. On the contrary, the DKO mice had 
a significantly decreased viral burden in multiple tissues, and significantly dampened 
inflammatory responses as well. Due to the fact that in humans A2M has been examined in the 
clinical settings as a maker for several diseases, it is clear that this protein is a crucial immune-
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regulatory protein for many diseases processes, and subsequently its role(s) in viral infections 
and associated disease warrants further investigations. Studies that seek to elucidate the 
mechanisms behind alpha-macroglobulins and their role in flaviviral infections are necessary to 
take the next step towards developing clinically applicable therapeutic options for infected 
individuals.  
 
 
4.2 Future Directions: 
Future studies are necessary to develop a further understanding of the functional role of alpha-
macroglobulins during flavivirus infections. Due to the fact that it has been previously shown 
that alpha-macroglobulins can bind to closely related flaviviruses such as Dengue virus (DENV) 
and enhance their infections in vitro, similar in vitro experiments should also be performed with 
WNV and JEV.36 Infection studies performed in vitro on cell populations isolated from WT and 
alpha-macroglobulin deficient (DKO) mice would allow us to determine whether the absence of 
alpha-macroglobulins has an effect on infections with WNV or JEV in vitro and which cell types 
show a greater enhancement of infection. Following the initial experiments and data analysis, 
similar in vitro infection studies with human cell types would be of interest to compare with 
mouse cell infection experiments. In this approach we can determine how the presence of alpha-
macroglobulins translates from mouse tissue to human tissue. On the other hand, because we 
know that A2M binds to the LRP receptor in human cells, in vitro receptor blockade experiments 
could be performed on cell types where an enhanced infection occurs in the presence of alpha-
macroglobulins in mice. Using this approach, we can determine which cell types are most critical 
for enhancement of flaviviral infections in human cell types in the presence of A2M in vitro, and 
subsequently attempt to block enhancement of the infection by inhibiting the LRP receptor. If the 
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receptor blocking approach is unsuccessful, an alternate approach would be to perform a co-
immunoprecipitation assays to determine first if WNV binds to the A2M protein, allowing for 
enhancement of infection, and if so determine the binding site of the virus to the protein. With 
this approach, certain sites on the A2M protein could be blocked which have been shown to bind 
the virus, and resultantly prevent binding of the virus to A2M. Once either receptor blocking, or 
the binding site for virus on the A2M protein has been tested and established in vitro, in vivo 
studies could be performed as well once a blocking technique has been established. Furthermore, 
these experiments can be performed with other closely related flaviviruses for a comparative 
analysis on viral pathogenesis as it relates to the presence and absence of alpha-macroglobulins.  
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